ONCOLYTICS BIOTECH INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.59 CAD | -5.92% |
|
-0.62% | -11.17% |
| May. 09 | Oncolytics Biotech Reports a First-Quarter Loss of Near $7 Million | MT |
| May. 09 | Transcript : Oncolytics Biotech Inc., Q1 2024 Earnings Call, May 09, 2024 |
Presentation Operator MessageOperator (Operator)Welcome to Oncolytics Biotech's Fourth Quarter...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Companyâs primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.
Calendar
Sell
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
1.59
CAD
Average target price
6.625
CAD
Spread / Average Target
+316.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.17% | 87.77M | |
| +17.96% | 44.96B | |
| +1.17% | 42.65B | |
| +48.77% | 41.85B | |
| -4.27% | 29.04B | |
| +11.42% | 26.08B | |
| -21.39% | 19.03B | |
| +4.86% | 12.75B | |
| +27.29% | 12.06B | |
| -3.50% | 11.75B |
- Stock Market
- Equities
- ONC Stock
- News Oncolytics Biotech Inc.
- Transcript : Oncolytics Biotech Inc., Q4 2022 Earnings Call, Mar 03, 2023
